Retraction Note: RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine(Oncogene, 10.1038/sj.onc.1207272);RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine

Oncogene

Volumn 23, Issue 8, 2004, Pages 1539-1548

  Duxbury, Mark S ^a   Ito, Hiromichi ^a   Zinner, Michael J ^a   Ashley, Stanley W ^a   Whang, Edward E ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cancer; Gemcitabine; Pancreatic adenocarcinoma; Ribonucleotide reductase; RNA interference; siRNA

Indexed keywords

ANTINEOPLASTIC AGENT; GEMCITABINE; PYROPHOSPHATE; RIBONUCLEOTIDE REDUCTASE; RNA; SMALL INTERFERING RNA; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE; RIBONUCLEOSIDE DIPHOSPHATE REDUCTASE; RIBONUCLEOTIDE REDUCTASE M2;

ANIMAL MODEL; ARTICLE; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; ENZYME SUBUNIT; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; RNA INTERFERENCE; ADENOCARCINOMA; ANIMAL; CANCER TRANSPLANTATION; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG POTENTIATION; GENETICS; MALE; METABOLISM; NUDE MOUSE; PANCREAS TUMOR; TIME; TUMOR CELL LINE; XENOGRAFT;

ANIMALIA;

ADENOCARCINOMA; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; DEOXYCYTIDINE; DRUG SYNERGISM; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PANCREATIC NEOPLASMS; RIBONUCLEOSIDE DIPHOSPHATE REDUCTASE; RNA, SMALL INTERFERING; TIME FACTORS; TRANSPLANTATION, HETEROLOGOUS;

EID: 1542742114     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/s41388-023-02627-4     Document Type: Erratum

References (50)

1. Adjei AA, Dy GK, Erlichman C, Reid JM, Sloan JA, Pitot HC, Alberts SR, Goldberg RM, Hanson LJ, Atherton PJ, Watanabe T, Geary RS, Holmlund J and Dorr FA. (2003). Clin. Cancer Res., 9, 115-123.
2. Aoki Y, Cioca DP, Oidaira H, Kamiya J and Kiyosawa K. (2003). Clin. Exp. Pharmacol. Physiol., 30, 96-102.
3. Arlt A, Gehrz A, Muerkoster S, Vorndamm J, Kruse ML, Folsch UR and Schafer H. (2003). Oncogene, 22, 3243-3251.
4. Bergman AM, Pinedo HM and Peters GJ. (2002). Drug Resist. Updat., 5, 19-33.
5. Bertrand JR, Pottier M, Vekris A, Opolon P, Maksimenko A and Malvy C. (2002). Biochem. Biophys. Res. Commun., 296, 1000-1004.
6. Brummelkamp TR, Bernards R and Agami R. (2002a). Science, 296, 550-553.
7. Brummelkamp TR, Bernards R and Agami R. (2002b). Cancer Cell, 2, 243-247.
8. Burris III HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD and Von Hoff DD. (1997). J. Clin. Oncol., 15, 2403-2413.
9. Calzado MA, Macho A, Lucena C and Munoz E. (2000). Clin. Exp. Immunol., 120, 317-323.
10. Cory JG. (1997). Purine and pyrimidine nucleotide metabolism. Devlin T (ed). Biochemistry with Clinical Correlations. Wiley-Liss: New York, pp. 489-523.
11. Editorial (2003). Nat. Cell Biol., 5, 489-490.
12. Endicott JA and Ling V. (1989). Annu. Rev. Biochem., 58, 137-171.
13. Eriksson S and Martin Jr DW. (1981). J. Biol. Chem., 256, 9436-9440.
14. Fan H, Villegas C and Wright JA. (1996). Proc. Natl. Acad. Sci. USA, 93, 14036-14040.
15. Filleur S, Courtin A, Ait-Si-Ali S, Guglielmi J, Merle C, Harel-Bellan A, Clezardin P and Cabon F. (2003). Cancer Res., 63, 3919-3922.
16. Fujioka S, Sclabas GM, Schmidt C, Frederick WA, Dong QG, Abbruzzese JL, Evans DB, Baker C and Chiao PJ. (2003). Clin. Cancer Res., 9, 346-354.
17. Goan YG, Zhou B, Hu E, Mi S and Yen Y. (1999). Cancer Res., 59, 4204-4207.
18. Gorelik E, Kim M, Duty L, Henion T and Galili U. (1993). Clin. Exp. Metastasis, 11, 439-452.
19. Grant CE, Valdimarsson G, Hipfner DR, Almquist KC, Cole SP and Deeley RG. (1994). Cancer Res., 54, 357-361.
20. Guittet O, Hakansson P, Voevodskaya N, Fridd S, Graslund A, Arakawa H, Nakamura Y and Thelander L. (2001). J. Biol. Chem., 276, 40647-40651.
21. Heinemann V, Hertel LW, Grindey GB and Plunkett W. (1988). Cancer Res., 48, 4024-4031.
22. Inayat MS, Chendil D, Mohiuddin M, Elford HL, Gallicchio VS and Ahmed MM. (2002). Cancer Biol. Ther., 1, 539-545.
23. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E and Thun MJ. (2003). CA Cancer J. Clin., 53, 5-26.
24. Jong AY, Yu K, Zhou B, Frgala T, Reynolds CP and Yen Y. (1998). J. Biomed. Sci., 5, 62-68.
25. Jung CP, Motwani MV and Schwartz GK. (2001). Clin. Cancer Res., 7, 2527-2536.
26. Kelley JR, Fraser MM, Schweinfest CW, Vournakis JN, Watson DK and Cole DJ. (2001). Surgery, 130, 280-288.
27. Kunsch C, Ruben SM and Rosen CA. (1992). Mol. Cell. Biol., 12, 4412-4421.
28. Lee Y, Vassilakos A, Feng N, Lam V, Xie H, Wang M, Jin H, Xiong K, Liu C, Wright J and Young A. (2003). Cancer Res., 63, 2802-2811.
29. Li K, Lin SY, Brunicardi FC and Seu P. (2003). Cancer Res., 63, 3593-3597.
30. McClarty GA, Chan AK, Engstrom Y, Wright JA and Thelander L. (1987). Biochemistry, 26, 8004-8011.
31. Monteith DK, Henry SP, Howard RB, Flournoy S, Levin AA, Bennett CF and Crooke ST. (1997). Anticancer Drug Des., 12, 421-432.
32. Muerkoster S, Arlt A, Witt M, Gehrz A, Haye S, March C, Grohmann F, Wegehenkel K, Kalthoff H, Folsch UR and Schafer H. (2003). Int. J. Cancer, 104, 469-476.
33. Nieth C, Priebsch A, Stege A and Lage H. (2003). FEBS Lett., 545, 144-150.
34. Pavloff N, Rivard D, Masson S, Shen SH and Mes-Masson AM. (1992). DNA Seq., 2, 227-234.
35. Pessara U and Koch N. (1990). Mol. Cell. Biol., 10, 4146-4154.
36. Plunkett W, Huang P, Searcy CE and Gandhi V. (1996). Semin. Oncol., 23, 3-15.
37. Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R and Gandhi V. (1995). Semin. Oncol., 22, 3-10.
38. Raitano AB, Scuderi P and Korc M. (1990). Pancreas, 5, 267-277.
39. Reichard P. (1978). Fed. Proc., 37, 9-14.
40. Reichard P. (1985). Basic Life Sci., 31, 33-45.
41. Sclabas GM, Fujioka S, Schmidt C, Evans DB and Chiao PJ. (2003). Int. J. Gastrointest. Cancer, 33, 15-26.
42. Shen Z, Peedikayil J, Olson GK, Siebert PD and Fang Y. (2002). Biotechniques, 32(5), 1168, 1170-2, 1174 passim.
43. Sun FX, Tohgo A, Bouvet M, Yagi S, Nassirpour R, Moossa AR and Hoffman RM. (2003). Cancer Res., 63, 80-85.
44. Tanaka H, Arakawa H, Yamaguchi T, Shiraishi K, Fukuda S, Matsui K, Takei Y and Nakamura Y. (2000). Nature, 404, 42-49.
45. Thelander L and Berg P. (1986). Mol. Cell. Biol., 6, 3433-3442.
46. Thelander M, Graslund A and Thelander L. (1985). J. Biol. Chem., 260, 2737-2741.
47. Wright JA, Alam TG, McClarty GA, Tagger AY and Thelander L. (1987). Somat. Cell Mol. Genet., 13, 155-165.
48. Zhou B, Mo X, Liu X, Qiu W and Yen Y. (2001). Cytogenet. Cell Genet., 95, 34-42.
49. Zhou BS, Hsu NY, Pan BC, Doroshow JH and Yen Y. (1995). Cancer Res., 55, 1328-1333.
50. Zhou BS, Tsai P, Ker R, Tsai J, Ho R, Yu J, Shih J and Yen Y. (1998). Clin. Exp. Metastas., 16, 43-49.